Anti-CD45 RIT with 131Iodine (131I)-apamistamab (Iomab-B), is in a Phase III clinical trial as a myeloablative targeted conditioning regimen prior to allogeneic stem cell transplant in patients with active relapsed/refractory acute myeloid leukemia (AML). This evidence concerns the gene PTPRC and acute myeloid leukemia.